sitravatinib + pembrolizumab + enfortumab vedotin

**sitravatinib + pembrolizumab + enfortumab vedotin** is an investigational combination regimen comprising three distinct oncology agents: - **Sitravatinib** is a spectrum-selective receptor tyrosine kinase inhibitor (RTKI), targeting the TAM family (TYRO3, AXL, MER), split kinase family receptors, and several other RTKs. It acts by blocking pathways implicated in resistance to checkpoint inhibitors and modulating the tumor microenvironment to enhance anti-tumor immunity. - **Pembrolizumab** is a humanized monoclonal antibody directed against programmed cell death protein 1 (**PD-1**) receptor. By blocking PD-1, it enhances the immune system’s ability to detect and destroy tumor cells (checkpoint inhibitor). - **Enfortumab vedotin** is an antibody-drug conjugate (ADC) targeting **Nectin-4** on tumor cells, delivering the cytotoxic microtubule-disrupting agent monomethyl auristatin E (MMAE) to induce tumor cell apoptosis. This combination is primarily being explored for advanced or metastatic urothelial carcinoma, especially in patients previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy. It aims to overcome resistance to immunotherapies and expand treatment options in cisplatin-ineligible and treatment refractory populations[2][5].